PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Oral anticoagulation is not effective in patients with atrial high-rate episodes

NOAH-AFNET 6 trial presented in a Hot Line Session today at ESC Congress 2023

2023-08-25
(Press-News.org) Amsterdam, Netherlands – 25 Aug 2023: Blood thinners (anticoagulants) cause bleeding without preventing stroke in patients with atrial high rate episodes (AHRE),  but without electrocardiogram (ECG)-diagnosed atrial fibrillation, according to late breaking research presented in a Hot Line session today at ESC Congress 2023 and simultaneously published in the New England Journal of Medicine.1

Anticoagulants prevent strokes in patients with atrial fibrillation but are not effective in those without atrial fibrillation, for example in patients with heart failure. Atrial high-rate episodes (AHRE) are short and rare atrial arrhythmias that resemble atrial fibrillation detected by implanted pacemakers, defibrillators, and loop recorders. AHRE are found in 10-30% of patients with implanted devices.2 While AHRE are associated with an increased risk of stroke, the risk is lower than for those with atrial fibrillation. ESC guidelines recommend oral anticoagulation to prevent stroke in patients with atrial fibrillation and increased stroke risk and propose individualised decisions in patients with AHRE, but without ECG-documented atrial fibrillation.3

NOAH-AFNET 6 was the first trial to investigate the efficacy and safety of oral anticoagulation in patients with AHRE, but without ECG-documented atrial fibrillation.4 The randomised, double-blind, double-dummy trial compared the anticoagulant edoxaban to placebo in patients ≥65 years with AHRE episodes ≥6 minutes detected by implantable devices, and with at least one additional stroke risk factor (heart failure, hypertension, diabetes, prior stroke or transient ischaemic attack, vascular disease, or age ≥75 years). This patient population was outside the approved indication of edoxaban.

In 206 sites across 18 European countries, patients were randomly allocated in a 1:1 fashion to anticoagulation or no anticoagulation. Anticoagulation consisted of edoxaban in the dose approved for stroke prevention in atrial fibrillation (60 mg once daily, reduced to 30 mg once daily according to approved dose reduction criteria for stroke prevention in atrial fibrillation). No anticoagulation consisted of placebo containing no active compound or aspirin 100 mg once daily in patients with an indication for antiplatelet therapy. The primary outcome was a composite of stroke, systemic embolism, or cardiovascular death. The safety outcome was a composite of major bleeding and all-cause death. All patients were followed until the end of the trial.

The primary, modified intention-to-treat analysis population consisted of 2,536 patients who received at least one dose of study drug. Patients were elderly with multiple stroke risk factors: the mean age was 78 years, 37% were women and the median CHA2DS2-VASc score was 4.5 The median AHRE duration at baseline was 2.8 hours without an upper limit, and 97% of AHRE showed atrial rates >200 beats per minute, clearly resembling atrial fibrillation.

The trial was stopped early due to safety signals and a trend towards futility for efficacy after enrolment of all planned patients. The primary efficacy outcome occurred in 83 patients in the anticoagulation group (3.2%/year) and in 101 patients in the no anticoagulation group (4.0%/year), for a hazard ratio (HR) of 0.81 (95% confidence interval [CI] 0.6-1.1]; p=0.15). The stroke rate was low in both randomised groups (without anticoagulation 1.1%/year, with anticoagulation 0.9%/year). The primary safety outcome occurred in 149 patients in the anticoagulation group (5.9%/year) and in 114 patients in the no anticoagulation group (4.5%/year), for a HR of 1.3 (95% CI 1.0-1.7; p=0.03). The difference in safety outcomes was driven by an expected increase in major bleeding in patients receiving anticoagulation (HR 2.10; 95% CI 1.30-3.38; p=0.002). ECG-diagnosed atrial fibrillation developed in 462/2536 patients (18%; 8.7%/year).

Principal investigator Paulus Kirchhof of the University Heart & Vascular Center Hamburg, Germany said: “The NOAH-AFNET 6 trial found that oral anticoagulation in patients with AHRE increases bleeding without reducing a composite outcome of stroke, systemic embolism, or cardiovascular death. The increased bleeding on anticoagulation therapy was expected. The low stroke rate with and without anticoagulation was unexpected. The results of NOAH-AFNET 6 clearly suggest to demand ECG documentation of atrial fibrillation prior to initiation of oral anticoagulation. Further research is needed to better understand the stroke risk in patients with very rare and short atrial arrhythmias.”

 

ENDS

Notes to editors

 

Authors: ESC Press Office
Mobile: +336 61 40 18 84

Email: press@escardio.org

The hashtag for ESC Congress 2023 is #ESCCongress

Follow us on Twitter @ESCardioNews 

 

Funding: DZHK, Daiichi Sankyo Europe.

 

Disclosures: NOAH - AFNET 6 was partially funded by BMBF (German Ministry of Education and Research, Berlin, Germany) through the DZHK (German Center for Cardiovascular Research, Berlin, Germany, grant number FKZ 81X2800182) and by Daiichi Sankyo Europe. Further support was provided by European Union CATCH ME (grant agreement No 633196) to Paulus Kirchhof and AFNET; AFFECT-EU (grant agreement 847770) to Paulus Kirchhof; MAESTRIA (grant agreement 965286) to Andreas Goette, Ulrich Schotten and AFNET; British Heart Foundation (PG/17/30/32961; AA/18/2/34218); German Research Foundation (Ki 509167694); DZHK (grant numbers 81Z0710116 and 81Z0710110) and Leducq Foundation.

 

Acknowledgements: The sponsor of the investigator-initiated NOAH – AFNET 6 trial was the German Atrial Fibrillation Network (AFNET).

 

References and notes

1NOAH-AFNET 6 will be discussed during Hot Line 1 on Friday 25 August at 11:15 to 12:15 CEST in room Amsterdam.

Kirchhof P, et al. Anticoagulation with edoxaban in patients with atrial high rate episodes. N Engl J Med. 25 August 2023. doi:10.1056/NEJMoa2303062

2Toennis T, Bertaglia E, Brandes A, et al. The influence of atrial high-rate episodes on stroke and cardiovascular death: an update. Europace. 2023. https://doi.org/10.1093/europace/euad166

3Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42:373-498.

4Kirchhof P, Blank BF, Calvert M, et al. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017;190:12-18.

5CHA2DS2-VASc: Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65 to 74 years, Sex category (female).

 

About ESC Congress 2023

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Amsterdam and online – from 25 to 28 August. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

END


ELSE PRESS RELEASES FROM THIS DATE:

Colchicine fails to reduce primary outcomes in COP-AF trial but encouraging signals found

2023-08-25
Amsterdam, Netherlands – 25 Aug 2023: Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1 Perioperative AF occurs in approximately 10% of patients after major thoracic surgery, while MINS has an incidence of about 20% in the same patient population.2 Patients with perioperative AF and MINS have a poor prognosis.3,4 High levels ...

First ESC Guidelines covering all acute coronary syndromes published today

2023-08-25
Amsterdam, Netherlands – 25 Aug 2023:  The European Society of Cardiology (ESC) Guidelines on acute coronary syndromes are published online today in European Heart Journal.1 The document covers the management of unstable angina and all types of acute myocardial infarction. “Time is critical in acute coronary syndromes. When an artery supplying the heart with blood becomes blocked, the quicker we open the artery and restore flow, the less damage occurs to the heart muscle,” said Guidelines task force ...

First international guidelines on heart muscle diseases published today

2023-08-25
Amsterdam, Netherlands – 25 Aug 2023:  The European Society of Cardiology (ESC) Guidelines on cardiomyopathies are published online today in European Heart Journal.1 This is the first international guideline document to include all cardiomyopathy subtypes, and the first time that specific recommendations are made for cardiomyopathies other than hypertrophic cardiomyopathy. “This pioneering document reflects the advances in genetics and cardiac imaging and the advent of new treatments that target specific causes of disease,” said Guidelines task force chairperson Dr. Elena Arbelo of the Hospital Clinic, University of Barcelona, Spain. “At the ...

Recommendations to reduce cardiovascular risk in patients with diabetes published today

2023-08-25
Amsterdam, Netherlands – 25 Aug 2023:  Patients with type 2 diabetes are more than twice as likely to develop cardiovascular disease (CVD) than their healthy peers. Advice to lower that risk is launched today in the 2023 European Society of Cardiology (ESC) Guidelines for the management of cardiovascular disease in patients with diabetes, published in European Heart Journal.1 “Patients with type 2 diabetes have a two- to four-fold higher risk of coronary artery disease, stroke, heart failure, atrial fibrillation and peripheral artery disease compared to those without type 2 diabetes and when CVD occurs, the prognosis ...

Patients urged to be vigilant about cardiac infections

2023-08-25
Amsterdam, Netherlands – 25 Aug 2023:  Patients with specific cardiac conditions such as valvular heart disease and congenital abnormalities, or those requiring a pacemaker, should practice good dental and skin hygiene to help prevent rare but potentially deadly infections of the heart’s inner lining and valves, according to European Society of Cardiology (ESC) Guidelines on infective endocarditis, published online today in European Heart Journal.1 “Infective endocarditis is an uncommon but very serious disease that can present with ...

Focused update of ESC Heart Failure Guidelines published today

2023-08-25
Amsterdam, Netherlands – 25 Aug 2023:  A focused update of the European Society of Cardiology (ESC) Heart Failure Guidelines is published online today in European Heart Journal following the results of major new trials that should change the management of patients with heart failure.1 “Heart failure is a fast-moving area of research and exciting new trials are expanding the treatment options for patients,” said Guidelines task force chairperson Professor Theresa McDonagh of King’s College Hospital, London, UK. “This focused update incorporates the latest evidence-based treatments ...

Cancer drug development yesterday, today and tomorrow

Cancer drug development yesterday, today and tomorrow
2023-08-25
“One can expect that artificial intelligence (AI) will play some role in the future drug development.” BUFFALO, NY- August 25, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on August 17, 2023, entitled, “Cancer drug development yesterday, today and tomorrow.” In this new editorial, researchers Elzbieta Izbicka and Robert T. Streeper from New Frontier Labs discuss the history of cancer drug development and how it has evolved over time. The editorial also highlights the current state of cancer drug development and ...

How fast does the charge migrate in molecules?

How fast does the charge migrate in molecules?
2023-08-25
To discover how light interacts with molecules, the first step is to follow electron dynamics, which evolve at the attosecond timescale. The dynamics of this first step have been called charge migration (CM). CM plays a fundamental role in chemical reactions and biological functions associated with light–matter interaction. For years, visualizing CM at the natural timescale of electrons has been a formidable challenge in ultrafast science due to the ultrafine spatial (angstrom) and ultrafast temporal ...

AI analysis finds younger AFib patients benefit from MRI-guided ablation treatments

2023-08-25
Younger atrial fibrillation (AFib) patients are most likely to benefit from more personalized, MRI-guided ablation treatments to correct irregular heart rhythms, according to a new artificial intelligence-guided analysis of results from the DECAAF II trial, one of the largest global studies of treatments for heart arrhythmias. Tulane University researchers presented the findings at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam this week. There’s been debate among physicians on whether going beyond traditional ablation treatments provides a benefit to patients. In 2021, the ...

European Society of Cardiology calls for competency-based cardiac imaging

2023-08-25
Sophia Antipolis, 25 August 2023:  Competency-based cardiac imaging delivery is needed for effective and efficient patient care, according to a European Society of Cardiology (ESC) statement published today in European Heart Journal, a journal of the ESC.1 All seven ESC subspeciality associations have endorsed the document, namely the European Association of Cardiovascular Imaging (EACVI), Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Preventive Cardiology (EAPC), European Association ...

LAST 30 PRESS RELEASES:

Home- vs office-based narrowband UV-B phototherapy for patients with psoriasis

Major boost in carbon capture and storage essential to reach 2°C climate target

‘Invisible forest’ of algae thrives as ocean warms

How do rare genetic variants affect health? AI provides more accurate predictions

Replacing hype about artificial intelligence with accurate measurements of success

Researchers harness AI to repurpose existing drugs for treatment of rare diseases

Combination treatment improves response to immunotherapy for lung cancer

Nanostructures in the deep ocean floor hint at life’s origin

Humbug damselfish use 'motion dazzle' to evade predators

Can a drug-free nasal spray protect against deadly respiratory infections?

Do natural disasters jeopardize women’s reproductive health?

Can cosmic radiation in outer space affect astronauts’ long-term cognition?

Do preventive health technologies promote or harm consumers’ wellbeing?

Preclinical studies suggest a drug-free nasal spray could ward off respiratory infections

Campylobacter jejuni-specific antibody gives hope to vaccine development

A viral close-up of HTLV-1

Virtual reality can help pedestrians and cyclists swerve harmful pollutants – study

Neuroscience luminary Hermona Soreq sheds light on the roles of RNA regulators in neurodegenerative diseases

Ancient reef-builders dodged extinction — at least temporarily

Citizen scientists help discover microplastics along the entire German coastline

Rising waters, waning forests: How scientists are using tree rings to study how rising sea levels affect coastal forests

Night-time noise linked to restless nights for airport neighbours

Fossils from the Adriatic Sea show a recent and worrying reversal of fortunes

With curtailed carbon emissions, corals can survive climate change

Global prevalence of short-sightedness in children and teens set to top 740 million cases by 2050

Urgent rethink of bottled water’s huge and growing toll on human and planetary health

Women still missing out on treatment for their No 1 killer—cardiovascular disease

Palestinian education ‘under attack’, leaving a generation close to losing hope, study warns

Semaglutide improves outcomes for obese patients with common skin condition, new study shows

Could GLP1RA drugs lower high iron levels?

[Press-News.org] Oral anticoagulation is not effective in patients with atrial high-rate episodes
NOAH-AFNET 6 trial presented in a Hot Line Session today at ESC Congress 2023